Effects of empagliflozin on exercise tolerance and left ventricular diastolic function in patients with heart failure with preserved ejection fraction and type 2 diabetes: a prospective single-center study

Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

“…Five studies were post hoc and subgroup analyses of large-scale cardiovascular outcome trials: SCORED ( 43 ), DECLARE-TIMI 58 ( 44 ), SOLOIST-WHF ( 45 ), VERTIS CV ( 29 ), and CANDLE ( 46 ). In addition, we included two smaller studies, which were conducted in patients with HFpEF and conduct in Russia ( 47 ) and China ( 48 ), respectively. Dapagliflozin (10 mg per day) was used in three RCTs ( 41 , 44 , 48 ), empagliflozin (10 mg per day) was used in three RCTs ( 30 , 39 , 47 ), canagliflozin (100 mg per day) was used in two RCTs ( 42 , 46 ), sotagliflozin (200 mg per day) was used in two RCTs ( 43 , 45 ), and ertugliflozin (5 mg per day) ( 29 ) and luseogliflozin (2.5 mg per day) ( 40 ) were used in one RCT each.…”

“…In addition, we included two smaller studies, which were conducted in patients with HFpEF and conduct in Russia ( 47 ) and China ( 48 ), respectively. Dapagliflozin (10 mg per day) was used in three RCTs ( 41 , 44 , 48 ), empagliflozin (10 mg per day) was used in three RCTs ( 30 , 39 , 47 ), canagliflozin (100 mg per day) was used in two RCTs ( 42 , 46 ), sotagliflozin (200 mg per day) was used in two RCTs ( 43 , 45 ), and ertugliflozin (5 mg per day) ( 29 ) and luseogliflozin (2.5 mg per day) ( 40 ) were used in one RCT each. Seven studies were placebo-controlled trials ( 29 , 30 , 39 , 41 , 43 – 45 ), and the other five trials compared SGLT2 inhibitors with antidiabetics.…”

“…The data of 6MWTD, BNP and E/e’ were all changes from baseline to the end of the treatment. 6MWTD was reported in two RCTs ( 39 , 47 ), BNP was in 2 RCTs ( 41 , 42 ), and E/e’ was in 2 RCTs ( 46 , 48 ). The changes of NT-proBNP from baseline to the end of the treatment were reported in 3 trials ( 30 , 40 , 47 ), while the NT-proBNP at the end of the treatment were reported in other 3 trials ( 41 , 46 , 48 ).…”

“…6MWTD was reported in two RCTs ( 39 , 47 ), BNP was in 2 RCTs ( 41 , 42 ), and E/e’ was in 2 RCTs ( 46 , 48 ). The changes of NT-proBNP from baseline to the end of the treatment were reported in 3 trials ( 30 , 40 , 47 ), while the NT-proBNP at the end of the treatment were reported in other 3 trials ( 41 , 46 , 48 ). Of the 12 trials, 7 trials reported a total of 3,290 AEs ( 30 , 39 – 42 , 47 , 48 ).…”

“…The changes of NT-proBNP from baseline to the end of the treatment were reported in 3 trials ( 30 , 40 , 47 ), while the NT-proBNP at the end of the treatment were reported in other 3 trials ( 41 , 46 , 48 ). Of the 12 trials, 7 trials reported a total of 3,290 AEs ( 30 , 39 – 42 , 47 , 48 ). Two studies using a left ventricular ejection fraction > 40% as a cut-off point for HFpEF ( 30 , 39 ), and four studies using a left ventricular ejection fraction > 45% as a cut-off point for HFpEF ( 29 , 40 , 41 , 44 ), while the other trials used a threshold of left ventricular ejection fraction > 50% ( 42 , 43 , 45 – 48 ).…”